Volume 23, Number 5—May 2017
Dispatch
Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium
Gerald L. Murray
, Catriona S. Bradshaw, Melanie Bissessor, Jennifer A. Danielewski, Suzanne M. Garland, Jørgen S. Jensen, Christopher K. Fairley, and Sepehr N. Tabrizi
, Catriona S. Bradshaw, Melanie Bissessor, Jennifer A. Danielewski, Suzanne M. Garland, Jørgen S. Jensen, Christopher K. Fairley, and Sepehr N. Tabrizi
Table 2
Samples containing changes in key amino acids of ParC and GyrA from 140 patients with Mycoplasma genitalium infection, Melbourne, Australia, July 2012 through June 2013*
| Patient no./sex | Sample | Log10 load, GEQ† | Treatment (moxifloxacin) outcome | SNPs in parC |
SNPs in gyrA |
||||||
| A247C
S83R |
G248T
S83I |
G259A
D87N |
G285A
M95I |
G295A
D99N |
G295T
D99Y |
A296G
D99G |
|||||
| 1/F | Cervical swab | 4.73 | Failure | – | + | – | + | – | – | – | |
| 2/M | Urine | 2.94 | Failure | – | + | – | + | – | – | – | |
| 3/F | Anal swab | 2.15 | Failure | – | + | – | – | + | – | – | |
| 4/M | Urine | 3.80 | Failure | – | + | – | – | – | – | + | |
| 5/M | Urethral swab | 5.10 | Failure | + | – | – | – | – | + | – | |
| 6/M | Urine | 4.66 | Failure | + | – | – | – | – | – | – | |
| 7/F | Cervical swab | 1.82 | Success | – | + | – | + | – | – | – | |
| 8/M | Urine | 2.47 | Success | – | + | – | + | – | – | – | |
| 9/M | Urine | 1.82 | Success | – | + | – | – | – | – | – | |
| 10/M | Urine | 4.07 | Success | – | – | + | – | – | – | – | |
| 11/F | Urine | 2.47 | NT | – | + | – | – | – | – | – | |
| 12/M | Urine | 3.46 | NT | – | + | – | – | – | – | – | |
| 13/M | Urine | 4.51 | NT | – | + | – | – | – | – | – | |
| 14/M | Urine | 3.51 | NT | – | + | – | – | – | – | – | |
| 15/M | Urine | 2.25 | NT | – | + | – | – | – | – | – | |
| 16/M | Urine | 1.11 | NT | – | + | – | – | – | – | – | |
| 17/F | Urine | 1.94 | NT | – | + | – | – | – | – | – | |
| 18/M | Urine | 2.50 | NT | – | – | + | – | – | – | – | |
| 19/F | Cervical/swab | 3.08 | NT | – | – | + | – | – | – | – | |
*Dataset includes all failed treatments for moxifloxacin. GEQ, genome equivalent; NT, not treated with moxifloxacin because azithromycin treatment was successful; SNP, single-nucleotide polymorphism; +, sequencing of sample successful and SNP present; –, SNP absent.
†The log10 loads of M. genitalium were calculated per swab or 1 mL of urine. For all 155 patients in the parent cohort, loads varied from 0.84 to 6.17 (median 3.36).
Page created: April 17, 2017
Page updated: April 17, 2017
Page reviewed: April 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential